Bayer submits its extended half-life hemophilia A compound for marketing authorization in Japan (for specialized target groups only)

Pivotal studies with BAY94-9027 showed that bleed protection was achieved with extended dosing intervals
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news